Please ensure Javascript is enabled for purposes of website accessibility

Nonprofit Group Starts Multiple COVID-19 Clinical Studies

By Cory Renauer - Mar 21, 2020 at 6:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Potential coronavirus treatments from Regeneron, Sanofi, and Gilead Sciences will get more chances to prove themselves effective.

The independent research arm of a large nonprofit group responsible for thousands of clinical trials will run a few more to try and find an effective treatment for patients suffering from COVID-19. The Feinstein Institutes for Medical Research has already enrolled patients into three studies in partnerships with Gilead Sciences (GILD 0.80%)Regeneron (REGN 0.84%), and Sanofi (SNY 5.95%)

Rheumatoid arthritis and COVID-19

In 2017, Sanofi and Regeneron launched Kevzara for the treatment of rheumatoid arthritis, an autoimmune disease. The injected drug dials back the immune system in the same way as Actemra, a drug from Roche (RHHBY 4.07%) that recently earned approval in China as a treatment for severe cases of COVID-19. 

Coronavirus blood samples.

Image source: Getty Images.

The most severe cases of COVID-19 appear to be associated with cytokine release syndrome (CRS), a condition in which the immune system wildly overreacts to an invader -- in this case, the virus -- causing the production of a life-threatening level of inflammatory proteins in the body. Actemra was approved to treat CRS when caused by certain powerful cancer immunotherapies, but Kevzara's list of approved indications is limited to rheumatoid arthritis.

Experimental antiviral

With Gilead Sciences, the Feinstein Institute will run two studies with remdesivir, an experimental antiviral drug that may help reduce the intensity and duration of COVID-19 by stopping the coronavirus that causes it from replicating. While it's a step in the right direction, these aren't the first trials to test remdesivir's ability to halt the novel coronavirus.

In one trial, investigators will randomize approximately 400 patients with severe cases of COVID-19 into two groups receiving different treatment durations. In the second study, Researchers will enroll around 600 patients into groups that receive standard care or remdesivir. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.08 (0.80%) $0.50
Sanofi Stock Quote
Sanofi
SNY
$53.42 (5.95%) $3.00
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.64 (4.07%) $1.63
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$612.49 (0.84%) $5.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.